Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 43%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc has demonstrated promising clinical results for its leading candidate, icotrokinra, showcasing notable improvements in clinical response rates and endoscopic outcomes, which may drive significant growth in the inflammatory diseases market. The company's robust pipeline, underpinned by innovative peptide-based therapeutics and a strong business development track record, positions it favorably for momentum through anticipated key catalysts in 2025. Additionally, the submission of a New Drug Application for icotrokinra in psoriasis, coupled with data highlighting its efficacy in difficult-to-treat areas, further enhances the company's growth prospects as it prepares for market entry.

Bears say

Protagonist Therapeutics Inc faces significant challenges related to its pipeline candidates, particularly icotrokinra, as it is subject to inherent industry risks such as unexpected safety concerns, potential strategic partnership withdrawals, and increased regulatory and competitive pressures. Additionally, the company must navigate a complex commercial landscape, which includes pricing reform and the potential for cash needs that could lead to dilution of current shareholder value. Such uncertainties in clinical efficacy, marketability, and financial stability contribute to a negative outlook for Protagonist Therapeutics's stock performance.

Protagonist Therapeutics (PTGX) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 14 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.